4.2 Article

A retrospective cohort study of intensive gastric variceal ligation versus endoscopic gastric variceal obturation in the management of gastric variceal bleeding

Journal

ANNALS OF PALLIATIVE MEDICINE
Volume 11, Issue 3, Pages 1038-1047

Publisher

AME PUBL CO
DOI: 10.21037/apm-22-138

Keywords

Ligation; tissue adhesive; esophageal and gastric varices; liver cirrhosis

Funding

  1. Hebei Provincial Department of Science and Technology [182777117D]
  2. Chinese Foundation for Hepatitis Prevention and Control-TianQing Liver Disease Research Fund Subject, China [TQGB20200050]

Ask authors/readers for more resources

In the treatment of gastric variceal bleeding, ligation is more effective than gastric variceal obturation (GVO) in reducing the rebleeding rate and associated mortality. Independent predictors for rebleeding after initial treatment include the endoscopic treatment method, total bilirubin level, liver cancer, and diabetes. For mortality prediction, male sex, liver cancer, ascites, and rebleeding after initial treatment are independent predictors.
Background: Gastric variceal bleeding is often more serious and can be fatal. Currently, international consensus recommendations for the treatment of gastric variceal bleeding vary according to endoscopic classification. Few studies have investigated ligation versus gastric variceal obturation (GVO) for the treatment of gastric varices. Methods: The study included 79 patients with cirrhosis-induced bleeding from esophageal and fundal varices who were treated at the Second Hospital of Hebei Medical University between January 2016 and December 2020 and who met the inclusion criteria. Among them, 42 patients were included in the intensive gastric varices ligation (IGVL) group, and 37 were included in the GVO group. We conducted a retrospective cohort study to analyze the effectiveness and safety of these 2 treatments. Results: The rebleeding rate after initial treatment was significantly lower in the IGVL group than in the GVO group (23.8% vs. 48.6%, P<0.05). No significant between-group difference was observed in overall mortality (14.3% vs. 32.4%), 6-week mortality (0.0% vs. 2.7%), or 1-year mortality (11.9% vs. 13.5%, all P>0.05). The >1-year mortality and bleeding-related mortality rates were significantly higher in the GVO group than in the IGVL group (23.3% vs. 2.7%, P<0.05; 27.0% vs. 9.5%, P<0.05). The incidence of adverse events was 57.1% in the IGVL group and 48.6% in the GVO group, with no significant difference (P>0.05). Independent predictors for rebleeding after initial treatment were the use of GVO as endoscopic treatment, total bilirubin >17.1 mu mol/L, liver cancer, and diabetes. For mortality, the independent predictors were male sex, liver cancer, ascites, and rebleeding after initial treatment. Conclusions: Rebleeding after initial treatment was lower after IGVL than GVO. Independent predictors for rebleeding after initial treatment were endoscopic treatment method, total bilirubin >17.1 mu mol/L, liver cancer, and diabetes. For mortality, the independent predictors were male sex, liver cancer, ascites, and rebleeding after initial treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available